"","nct_id","last_update_submitted_date","registration_date","summary_results_date","study_type","phase","enrollment","recruitment_status","official_title","title","start_date","completion_date","primary_completion_date","has_summary_results","allocation","masking","main_sponsor","is_multicentric","facility_affiliation","city","country","region"
"1","NCT03919812",2019-04-17,2019-04-15,NA,"Interventional","Not Applicable",60,"Completed","Immunomodulatory Effect of Vitamin D Supplementation on Monocyte in Major Beta-thalassemia","Immunomodulatory Vitamin D in Thalassemia",2018-04-01,2018-08-15,2018-07-15,FALSE,NA,"None (Open Label)","OTHER",FALSE,"Klinik Thalassemia Rumah Sakit Dr. Hasan Sadikin Bandung","Bandung","Indonesia","LMIC"
"2","NCT00677339",2012-01-17,2008-05-12,NA,"Interventional","Phase 3",200,"Completed","Phase 3 Trial of Oral L-arginine and / or Vitamin D as Adjunctive Therapies in Pulmonary Tuberculosis in Papua Province, Indonesia.","L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB)",2008-06-01,2010-05-01,2010-02-01,FALSE,"Randomized","Quadruple","OTHER",FALSE,"Timika Tuberculosis Clinic and Community Hospital","Timika","Indonesia","LMIC"
"3","NCT01356095",2012-08-28,2011-05-17,NA,"Interventional","Not Applicable",28,"Completed","A Knowledge Translation Intervention for TB/HIV Treatment Adherence, in Zomba District, Malawi","A Knowledge Translation Intervention for TB/HIV Treatment Adherence, in Zomba District, Malawi",2011-03-01,2012-05-01,2012-03-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"Zomba District Health Centers, Dignitas International","Zomba","Malawi","LMIC"
"4","NCT02378207",2019-10-28,2015-02-12,2019-09-03,"Interventional","Phase 1",84,"Completed","A Randomized, Placebo-controlled, Partially Blinded Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of BCG Revaccination, H4:IC31, and H56:IC31 in Healthy, HIV-1-Uninfected Adolescent Participants","Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents",2015-05-01,2016-12-09,2016-10-31,TRUE,"Randomized","Quadruple","OTHER",FALSE,"Desmond Tutu HIV Foundation","Cape Town","South Africa","LMIC"
"5","NCT01241188",2015-04-16,2010-11-15,NA,"Interventional","Phase 2",253,"Completed","A Phase IIb Sensitivity Trial of the Diagnostic Agent C-Tb, When Given Intradermally by the Mantoux Technique to Adult Patients Recently Diagnosed With Active TB","A Trial of the C-Tb Skin Test, When Given Intradermally to Adult Patients Recently Diagnosed With Active Tuberculosis (TB)",2011-04-01,2011-12-01,2011-12-01,FALSE,"Randomized","Quadruple","OTHER",FALSE,"University of Cape Town Lung Institute (Pty) Ltd","Cape Town","South Africa","LMIC"
"6","NCT04482231",2020-07-17,2020-07-17,NA,"Observational",NA,9944,"Completed","Antibiotic Observatory for Respiratory Diseases, Apart From Tuberculosis and Reportable Diseases","Antibiotic Observatory for Respiratory Diseases, Apart From Tuberculosis and Reportable Diseases",2018-01-02,2018-08-31,2018-08-31,FALSE,NA,NA,"OTHER",FALSE,"Emergency department of fattouma bourguiba university hospital","Monastir","Tunisia","LMIC"
"7","NCT04916899",2021-06-01,2021-06-01,NA,"Observational",NA,47,"Completed","Study to Evaluate the Safety of the Use of doTBal (Rifampicin, Isoniazid, Pyrazinamide and Ethambutol) in Patients With Tuberculosis: Conduction of an Intensive Pharmacovigilance Program","Safety of doTBal® in Patients With Tuberculosis: Conduction of an Intensive Pharmacovigilance Program",2014-11-01,2016-09-01,2016-09-01,FALSE,NA,NA,"INDUSTRY",FALSE,"Laboratorio Silanes, S.A. de C.V.","Mexico City","Mexico","LMIC"
"8","NCT03137875",2017-04-28,2011-02-22,NA,"Observational",NA,122,"Completed","Evaluation of the PCR Using DNA Extracts From Stained Slides and Sputum Collected on Filter Paper for Identification and Detection of Tuberculosis and Multidrug Resistant (MDR) Tuberculosis","Evaluation of PCR Using DNA Extract From Slides and Filter Paper for the Detection of Tuberculosis and MDR-tuberculosis",2011-03-01,2012-12-01,2012-12-01,FALSE,NA,NA,"OTHER",FALSE,"Epicentre Mbarara Research Base","Mbarara","Uganda","LMIC"
"9","NCT01955824",2014-12-26,2013-09-25,NA,"Interventional","Phase 2/Phase 3",500,"Completed","""A RCT ON CLINICAL EFFICACY OF 1% vs. 2% LIGNOCAINE IN COUGH SUPPRESSION AND PAIN RELIEF IN PATIENTS UNDERGOING FLEXIBLE BRONCHOSCOPY""","A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy",2014-05-01,2014-11-01,2014-11-01,FALSE,"Randomized","Single","OTHER",FALSE,"Bronchoscopy suite, PGIMER","Chandigarh","India","LMIC"
"10","NCT01967134",2019-08-20,2013-10-18,2019-03-08,"Interventional","Phase 1",25,"Completed","Phase I Open Label Dose-Escalation Study to Evaluate the Safety and Immunogenicity of H56:IC31 (AERAS-456) in HIV-negative Adults With and Without Latent Tuberculosis Infection","Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis",2011-11-01,2013-06-01,2012-12-01,TRUE,"Non-Randomized","None (Open Label)","OTHER",FALSE,"SATVI Project Office, Brewelskloof Hospital","Worcester","South Africa","LMIC"
"11","NCT03278483",2019-04-25,2017-08-07,NA,"Interventional","Phase 4",396,"Completed","Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2","Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2 (TBL)",2019-02-28,2019-02-28,2019-02-28,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"Instituto Nacional de Ciencias Medicas y Nutrición","Mexico City","Mexico","LMIC"
"12","NCT01986543",2017-07-10,2013-11-12,NA,"Interventional","Phase 2",105,"Unknown status","Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection","Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection",2013-12-01,2017-12-01,2017-12-01,FALSE,"Randomized","None (Open Label)","OTHER_GOV",FALSE,"Mbarara Research Base","Mbarara PO box 1956, Mbarara","Uganda","LMIC"
"13","NCT02684240",2020-08-03,2016-02-02,NA,"Interventional","Phase 2",30,"Completed","A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis","A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis",2016-02-01,2018-04-11,2018-04-11,FALSE,"Randomized","Single","OTHER",FALSE,"Les Centres GHESKIO","Port-au-Prince","Haiti","LMIC"
"14","NCT02109874",2016-04-25,2014-03-28,NA,"Interventional","Phase 1",40,"Completed","A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS 404 When Administered as a Single Adjuvant Amount With Different Antigen Amounts in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection","A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404)",2008-12-01,2012-09-01,2010-12-01,FALSE,"Randomized","Triple","OTHER",FALSE,"South African Tuberculosis Vaccine Institute; Brewelskloof Hospital","Worcester","South Africa","LMIC"
"15","NCT01677871",2013-12-16,2012-08-30,NA,"Interventional","Not Applicable",120,"Unknown status","Study of Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease","Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease",2012-09-01,2014-09-01,2014-09-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"Institute of Liver and Biliary Sciences","New Delhi","India","LMIC"
"16","NCT00918086",2014-07-10,2009-06-10,NA,"Interventional","Phase 2",199,"Completed","Impact of Vitamin D Supplementation on Host Immunity to Mycobacterium Tuberculosis and Response to Treatment: Building Translational Research Capacity in Nutrition and Infectious Diseases in the Republic of Georgia","Impact of Vitamin D Supplementation on Host Immunity to Mycobacterium Tuberculosis and Response to Treatment",2009-07-01,2014-07-01,2012-09-01,FALSE,"Randomized","Triple","OTHER",FALSE,"National Center for tuberculosis and Lung diseases","Tbilisi","Georgia","LMIC"
"17","NCT00617643",2010-12-03,2008-02-05,NA,"Interventional","Phase 4",18,"Completed","Comparison of Nevirapine Levels With and Without Dose Escalation in HIV-infected Patients Commencing Antiretroviral Therapy Who Are Also Receiving Rifampicin Based Anti-tuberculous Therapy","Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis",2008-05-01,2010-12-01,2009-06-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"Infectious Diseases Institute, Faculty of Medicine, Makerere University","Kampala","Uganda","LMIC"
"18","NCT03032367",2017-07-26,2017-01-24,NA,"Interventional","Early Phase 1",24,"Completed","TASK-002: Bioequivalence of Bedaquiline 400mg Administered in Crushed Form Compared to Tablet Form in Healthy Male and Female Adults Under Fed Conditions (BDQ Crush Study)","TASK-002: Bioequivalence of Bedaquiline 400mg Administered in Crushed Form Compared to Tablet Form in Healthy Male and Female Adults Under Fed Conditions (BDQ Crush Study)",2016-11-10,2017-01-11,2016-12-09,FALSE,"Randomized","None (Open Label)","NETWORK",FALSE,"TASK Clinical Research Centre","Bellville","South Africa","LMIC"
"19","NCT01705041",2013-01-29,2012-08-21,NA,"Interventional","Not Applicable",700,"Completed","Preliminary Field Evaluation of a Point-of-Care Transaminase Test","Preliminary Evaluation of a Point-Of-Care Liver Function Test",2012-06-01,2012-12-01,2012-08-01,FALSE,NA,"None (Open Label)","OTHER",FALSE,"Hospital for Tropical Diseases","Ho Chi minh City","Vietnam","LMIC"
"20","NCT01785927",2013-02-05,2013-02-05,NA,"Interventional","Phase 1",40,"Unknown status","Clinical Trial Phase I of Antituberculosis Dry Powder Aerosols","The Safety of Tuberculosis Treatments by Oral Inhalation",2013-02-01,2013-04-01,2013-04-01,FALSE,"Randomized","Quadruple","OTHER",FALSE,"Songklanagarind Hospital","Hat Yai","Thailand","LMIC"
"21","NCT03918226",2019-04-15,2019-04-15,NA,"Interventional","Not Applicable",80,"Completed","Acute Presentation and Management of Abdominal Tuberculosis: A Ten-year Experience at a Tertiary Care Center in Pakistan","Acute Presentation and Management of Abdominal Tuberculosis: A Ten-year Experience at a Tertiary Care Center in Pakistan",2008-05-01,2018-04-30,2018-04-30,FALSE,NA,"None (Open Label)","OTHER_GOV",FALSE,"Services hospital","Lahore","Pakistan","LMIC"
"22","NCT02153528",2020-02-11,2014-05-26,2020-01-15,"Interventional","Phase 3",701,"Completed","Optimization of the TB Treatment Regimen Cascade","Optimization of the TB Treatment Regimen Cascade",2014-11-01,2017-08-01,2017-08-01,TRUE,"Randomized","None (Open Label)","OTHER",FALSE,"Damien Foundation Bangladesh TB project in Greater Mymensingh district (8 selected clinics)","Dhaka","Bangladesh","LMIC"
"23","NCT02349841",2018-09-11,2015-01-23,NA,"Interventional","Phase 2",46,"Completed","A Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem, Administered Intravenously, Plus Amoxycillin/CA and Faropenem, Administered Orally, Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed, Smear-positive Pulmonary Tuberculosis.","Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis",2014-09-01,2014-12-01,2014-12-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"TASK Foundation NPC","Cape Town","South Africa","LMIC"
"24","NCT01700790",2019-05-14,2012-10-02,NA,"Interventional","Phase 4",9,"Terminated","A Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir in Combination With Rifampin in HIV-1-infected Patients With Tuberculosis.","Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin",2016-02-01,2018-12-31,2018-11-17,FALSE,NA,"None (Open Label)","OTHER",FALSE,"Instituto Nacional de Infectologia Evandro Chagas - Fiocruz(INI), Laboratorio de Pesquisa Clinica em Micobacterioses(LAPCLINTB)","Rio de Janeiro","Brazil","LMIC"
"25","NCT01098474",2019-06-11,2010-03-18,2016-11-08,"Interventional","Phase 2",301,"Completed","Safety and Immunogenicity Study of GSK Biologicals' Candidate Tuberculosis Vaccine (692342) When Administered to Healthy Infants","Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants",2010-07-07,2012-03-16,2011-04-30,TRUE,"Randomized","None (Open Label)","INDUSTRY",FALSE,"GSK Investigational Site","Banjul","Gambia","LMIC"
"26","NCT02176772",2017-06-02,2014-06-23,NA,"Observational",NA,19,"Completed","The Effects of Tuberculosis on Dietary Iron Absorption and Systemic Iron Utilization: a Double Stable Isotope Study in Bagamoyo, Tanzania","Iron Absorption and Utilization During Tuberculosis and After Treatment",2015-04-01,2017-01-01,2017-01-01,FALSE,NA,NA,"OTHER",FALSE,"Tb-clinic, Bagamoyo Research and Training Centre","Bagamoyo","Tanzania","LMIC"
"27","NCT02953847",2017-05-09,2016-09-05,NA,"Interventional","Phase 1",21,"Completed","The Bioavailability of Rifampicin in Fixed Dose Combinations (FDCs) Widely Used in South Africa to Treat Drug-susceptible Tuberculosis (TB)","The Bioavailability of Rifampicin in (FDCs) Widely Used in South Africa to Treat Drug-susceptible (TB)",2016-11-01,2017-02-01,2017-02-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"Clinical Research Centre","Cape Town","South Africa","LMIC"
"28","NCT01698476",2016-02-04,2012-09-25,NA,"Interventional","Phase 2",390,"Completed","Immune Reconstitution in Tuberculosis Disease Using Antimicrobial Treatment With Vitamin D and Phenylbutyrate","Immune Reconstitution in Tuberculosis Disease",2012-09-01,2015-08-01,2015-08-01,FALSE,"Randomized","Quadruple","OTHER",FALSE,"Black Lion Hospital (BLH), Addis Ababa University, Faculty of Medicine","Addis Ababa","Ethiopia","LMIC"
"29","NCT00814671",2018-01-08,2008-12-24,2016-08-03,"Interventional","Phase 2",153,"Completed","A Phase 2 Randomized, Open-label Trial of Daily Rifapentine 450mg or 600mg in Place of Rifampicin 600mg for Intensive Phase Treatment of Smear-positive Pulmonary Tuberculosis","Study of Daily Rifapentine for Pulmonary Tuberculosis",2010-04-01,2014-09-01,2013-06-01,TRUE,"Randomized","None (Open Label)","OTHER",FALSE,"Universiy of Cape Town Lung Institute","Cape Town","South Africa","LMIC"
"30","NCT01378312",2014-03-14,2011-02-24,NA,"Interventional","Phase 1",12,"Completed","A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS-402 When Administered to HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection","A Study to Evaluate Safety and Immunogenicity of AERAS-402",2011-02-01,2012-03-01,2011-10-01,FALSE,"Randomized","Quadruple","OTHER",FALSE,"Lotus Labs","Bangalore","India","LMIC"
"31","NCT02558842",2016-08-01,2015-09-22,NA,"Interventional","Not Applicable",160,"Completed","Intervention in the Management of Post-high Tuberculosis Hospital Through Educational Strategy and Oversight Distance in a Region With High Prevalence of the Disease: Randomized Clinical Trial","Intervention in the Management of Post-high Tuberculosis Hospital Through Educational Strategy and Oversight Distance",2013-03-01,2015-12-01,2015-09-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"Alice Mânica Müller","Porto Alegre","Brazil","LMIC"
"32","NCT01119521",2017-01-05,2010-04-29,NA,"Interventional","Phase 1",82,"Completed","Phase I Study of Whether Preclearance of Latent M. Tuberculosis (MTB) Infection With Isoniazid (INH) Enhances Specific Immune Responses to MTB Following Subsequent BCG Revaccination in Healthy, HIV-Uninfected, Tuberculin Skin Test Positive Adults","Study of Pre-clearance of Latent Tuberculosis Infection And BCG Revaccination",2010-10-01,2013-07-01,2013-07-01,FALSE,"Randomized","None (Open Label)","NIH",FALSE,"University of Cape Town - Institute of Infectious Disease and Molecular Medicine","Cape Town","South Africa","LMIC"
"33","NCT01657656",2014-07-29,2012-08-02,NA,"Interventional","Not Applicable",350,"Completed","Vitamin D Supplementations as Adjunct to Anti-Tuberculosis Drugs in Mongolia","Vitamin D Supplementations as Adjunct to Anti-Tuberculosis Drugs in Mongolia",2012-10-01,2014-07-01,2014-05-01,FALSE,"Randomized","Double","OTHER",FALSE,"National Center for Communicable Dieases","Ulaanbaatar","Mongolia","LMIC"
"34","NCT03017378",2017-01-10,2017-01-04,NA,"Interventional","Phase 1",36,"Completed","A Randomized, Open Clinical Trial Phase 1 Vaccine TB/FLU-01L by Intranasal and Sublingual Application for Specific Immunotherapy Pulmonary Tuberculosis","Reactogenicity, Safety and Immunogenicity of a TB/FLU-01L Tuberculosis Vaccine",2013-10-01,2015-02-01,2014-04-01,FALSE,"Randomized","None (Open Label)","OTHER_GOV",FALSE,"National Center for Tuberculosis Problems, Kazakhstan","Almaty Qalasy","Kazakhstan","LMIC"
"35","NCT02729532",2019-04-19,2016-01-05,NA,"Observational",NA,776,"Completed","Z 31411 - The Effect of Xpert MTB/RIF on Patient Health Outcomes and Empirical TB Treatment Among Persons Living With HIV/AIDS: A Parallel-Group Prospective Cohort Study Under Real-World Conditions in Lusaka, Zambia","Effect of Xpert MTB/RIF on Patient Outcomes",2016-06-22,2018-02-09,2018-02-09,FALSE,NA,NA,"OTHER",FALSE,"Chelstone and Chilenje Health Centres","Lusaka","Zambia","LMIC"
"36","NCT01579214",2017-12-08,2012-04-13,2017-05-05,"Interventional","Not Applicable",183,"Completed","Cell Phone Messaging to Improve Communication of Critical Laboratory Results to Patients in Rural Uganda","Cell Phone Messaging to Improve Communication of Critical Laboratory Results to Patients in Rural Uganda",2012-07-01,2015-04-01,2013-12-01,TRUE,"Non-Randomized","None (Open Label)","OTHER",FALSE,"ISS Clinic, Mbarara Regional Referral Hospital","Mbarara","Uganda","LMIC"
"37","NCT00676754",2013-03-27,2008-05-08,NA,"Observational",NA,18544,"Unknown status","Epidemiology of Multidrug-Resistant Tuberculosis in Peru","Epidemiology of MDR-TB in Peru",2009-09-01,2014-09-01,2014-09-01,FALSE,NA,NA,"OTHER",FALSE,"Socios En Salud Sucursal Peru","Lima","Peru","LMIC"
"38","NCT01800487",2013-12-23,2013-02-21,NA,"Interventional","Not Applicable",80,"Completed","The Efficacy of Silymarin on the Prevention of Hepatotoxicity From Antituberculosis Drugs","The Efficacy of Silymarin on the Prevention of Hepatotoxicity From Antituberculosis Drugs",2012-01-01,2013-07-01,2013-06-01,FALSE,"Randomized","Quadruple","OTHER",FALSE,"Gastroenterology and Hepatology, Ramathibodi hospital","Bangkok","Thailand","LMIC"
"39","NCT02060006",2014-04-02,2014-02-07,NA,"Interventional","Phase 3",200,"Unknown status","A Double-Blind Randomized Placebo Controlled Trial for Prevention of Tuberculosis-Immune Reconstitution Inflammatory Syndrome With Non-Steroid Anti-Inflammatory Drugs (NSAIDs) in HIV-Infected Adults","TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial",2014-04-01,2015-04-01,2015-04-01,FALSE,"Randomized","Quadruple","OTHER",FALSE,"Stellenbosch University Tygerberg Hospital","Cape Town","South Africa","LMIC"
"40","NCT02430259",2020-06-27,2015-04-16,NA,"Interventional","Phase 3",566,"Completed","Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months for Tuberculosis Preventive Treatment: A Randomized Controlled Study in China","Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention",2015-03-01,2018-06-01,2018-06-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"Wenling No.1 People's Hospital, Zhejiang","Taizhou","China","LMIC"
"41","NCT03096379",2019-04-15,2017-03-15,NA,"Observational",NA,120,"Completed","Differentiating Gut Tuberculosis and Crohn's Disease Via Magnetic Resonance Enterography","MRI Differentiating Gut TB and Crohn's",2014-12-30,2019-03-30,2018-12-30,FALSE,NA,NA,"OTHER",FALSE,"The University of Hong Kong-Shenzhen Hospital","Shenzhen","China","LMIC"
"42","NCT00910806",2014-04-01,2009-05-07,NA,"Interventional","Phase 1",16,"Completed","A Phase I, Open-label, Single-sequence Drug-drug Interaction Trial to Investigate the Pharmacokinetic Interaction Between Steady-state Nevirapine and Single-dose TMC207 in HIV-1 Infected Subjects.","TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)",2009-06-01,2010-06-01,2010-06-01,FALSE,"Non-Randomized","None (Open Label)","INDUSTRY",FALSE,NA,"George","South Africa","LMIC"
"43","NCT01158755",2012-06-06,2010-07-07,NA,"Interventional","Phase 2",60,"Completed","Comparison of Intensive Treatment Regimens and Standard Treatment Regimen for Tuberculous Meningitis: Pharmacokinetics, Pharmacodynamics and Tolerability Study","Intensified Treatment Regimens for TB Meningitis: PK, PD and Tolerability Study",2010-10-01,2012-06-01,2011-12-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"Hasan Sadikin General Hospital","Bandung","Indonesia","LMIC"
"44","NCT00801606",2016-02-08,2008-12-02,NA,"Interventional","Phase 3",403,"Completed","Micronutrient Supplementation in Conjunction With Standard Anti-Tuberculosis Therapy in Paediatric (6 Months-15 Years) New Pulmonary Tuberculosis Patients","Micronutrient Supplementation in in Paediatric Pulmonary Tuberculosis",2008-12-01,2012-06-01,2012-06-01,FALSE,"Randomized","Quadruple","OTHER",FALSE,"Department of Pediatrics, All India Institute of Medical Sciences","New Delhi","India","LMIC"
"45","NCT01742364",2016-12-15,2012-11-30,2016-04-06,"Interventional","Not Applicable",96,"Completed","A Randomized Clinical Trial in Adults and Newborns to Compare the Safety, Reactogenicity and Immunogenicity of BCG Administration Via a Disposable Syringe Jet Injector (DSJI) to BCG Administration Via Syringe and Needle","Comparative Study of Bacille Calmette Guerin (BCG) Delivery Via Disposable Syringe Jet Injector and Needle & Syringe",2012-12-01,2013-12-01,2013-12-01,TRUE,"Randomized","Single","OTHER",FALSE,"SATVI, University of Cape Town","Cape Town","South Africa","LMIC"
"46","NCT01215110",2017-03-15,2010-09-30,2016-10-19,"Interventional","Phase 2",68,"Completed","A Phase II Dose Ranging Trial to Evaluate the Extended Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of TMC207 in Adult Patients With Newly Diagnosed, Uncomplicated, Smear-Positive, Pulmonary Tuberculosis.","Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)",2010-04-01,2010-09-01,2010-08-01,TRUE,"Randomized","Double","OTHER",FALSE,"Karl Bremer Hospital","Belville","South Africa","LMIC"
"47","NCT01311505",2012-06-21,2011-02-15,2012-03-23,"Interventional","Phase 1",21,"Completed","An Open Label, Single Dose, Randomized, Two-Way Cross-Over Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination Rifampicin + Isoniazid (Myrin© 2, Pfizer Inc) Tablet With The Reference Drug (Rimactane®, Novartis Sandoz) Capsule In Healthy Filipino Male Subjects","Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)",2011-04-01,2011-05-01,2011-05-01,TRUE,"Randomized","None (Open Label)","INDUSTRY",FALSE,"Pfizer Investigational Site","Dasmariñas City","Philippines","LMIC"
"48","NCT03255278",2017-12-25,2017-06-29,NA,"Interventional","Phase 1",60,"Completed","Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine ""GamTBvac"" Against the Tuberculosis. Comparative Placebo-controlled Study With a Two-fold Increase of the Vaccine Dose in Healthy Volunteers Aged 18-49 Years.","Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine ""GamTBvac"" Against the Tuberculosis.",2017-01-15,2017-12-13,2017-12-13,FALSE,"Randomized","Single","OTHER",FALSE,"Sechenov First Moscow State Medical University","Moscow","Russian Federation","LMIC"
"49","NCT01530568",2015-01-06,2012-01-24,NA,"Interventional","Not Applicable",341,"Completed","A Randomised Control Trial of a Standardised and User-friendly Real-time PCR Assay for the Diagnosis of TB Using Tracheal Aspirates Obtained From Patients in the ICU","Gene Xpert Diagnosis of TB Using Tracheal Aspirates From Intensive Care Unit (ICU) Patients",2010-08-01,2013-07-01,2013-07-01,FALSE,"Randomized","Single","OTHER",FALSE,"Groote Schuur Hospital, which operates within the Cape Town Central Health District of the Metro Region","Cape Town","South Africa","LMIC"
"50","NCT02043314",2014-01-22,2014-01-17,NA,"Interventional","Phase 1",28,"Completed","New Strategy for Treating Latent Tuberculosis Infection in Brazil: A Bioequivalence Study of Two Different Dosages of Isoniazid Tablet Formulations in Human Healthy Volunteers","A Bioequivalence Study of Two Different Dosages of Isoniazid Tablet Formulations in Human Healthy Volunteers",2008-10-01,2009-03-01,2008-10-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"Synchrophar - Ass. e Desenv. de Projetos Clínicos Ltda.","Campinas","Brazil","LMIC"
"51","NCT00691392",2012-08-15,2008-06-03,NA,"Interventional","Phase 1/Phase 2",26,"Completed","Linezolid Pharmacokinetics and Pharmacodynamics in the Treatment of Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis","Linezolid Pharmacokinetics (PK) in Multi-Drug Resistant (MDR)/Extensively-Drug Resistant (XDR) Tuberculosis (TB)",2009-04-01,2010-05-01,2010-05-01,FALSE,"Randomized","Triple","FED",FALSE,"King George V Hospital","Durban","South Africa","LMIC"
"52","NCT02043080",2017-08-02,2014-01-16,NA,"Interventional","Not Applicable",1436,"Completed","CIDRZ 1201 - Optimizing Clinical Outcomes in HIV-Infected Adults & Children Using Xpert MTB/RIF in Zambia","Optimizing Clinical Outcomes in HIV-Infected Adults & Children",2012-08-01,2017-04-01,2016-03-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"Centre for Infectious Disease Research in Zambia","Lusaka","Zambia","LMIC"
"53","NCT00608790",2012-07-23,2008-01-31,NA,"Interventional","Not Applicable",600,"Unknown status","Diagnostic Yield of Induced Sputum for Rapid Diagnosis of Pulmonary Tuberculosis","Rapid Diagnosis of Pulmonary Tuberculosis",2008-02-01,2013-04-01,2012-12-01,FALSE,"Non-Randomized","None (Open Label)","OTHER",FALSE,"University of Cape Town","Cape Town","South Africa","LMIC"
"54","NCT02174380",2014-07-07,2014-06-23,NA,"Interventional","Not Applicable",1900,"Unknown status","Cost-effectiveness of a Population-based Active TB Control Program for Tuberculosis, Lima, Peru","Effectiveness of Active Case Finding of Household Contacts in a Routine Tuberculosis (TB) Control Program",2012-10-01,2015-06-01,2014-12-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"Instituto de Medicina Tropicales ""Alexander von Humboldt"", Universidad Peruana Cayetano Heredia","San Martin de Porres","Peru","LMIC"
"55","NCT02520973",2017-08-15,2015-03-09,NA,"Interventional","Not Applicable",1400,"Completed","Screening for TB in Pregnancy A Supplement to: The Effect of Tuberculosis and Its Treatment on HIV-Infected Pregnant Women and Their Infants","Screening for TB in Pregnancy. on HIV-Infected Pregnant Women",2015-05-01,2017-06-30,2017-06-30,FALSE,"Non-Randomized","None (Open Label)","OTHER",FALSE,"Perinatal HIV Research Unit","Klerksdorp","South Africa","LMIC"
"56","NCT01924286",2018-01-18,2013-08-12,NA,"Interventional","Phase 3",240,"Completed","Preventing Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone","Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone",2013-08-30,2017-04-01,2016-04-01,FALSE,"Randomized","Quadruple","OTHER",FALSE,"Site B Khayelitsha HIV/TB clinic","Cape Town","South Africa","LMIC"
"57","NCT02946762",2019-03-11,2016-09-14,NA,"Interventional","Not Applicable",419,"Completed","Z 31501 - Treatment as Prevention (TasP) in Correctional Facilities in Zambia and South Africa","TasP in Correctional Facilities",2016-02-01,2018-03-31,2018-03-31,FALSE,NA,"None (Open Label)","OTHER",FALSE,"Lusaka Central Corrections ART Clinic","Lusaka","Zambia","LMIC"
"58","NCT01159886",2010-07-09,2010-07-09,NA,"Interventional","Not Applicable",216,"Unknown status","Patient-posture and Ileal-intubation During Colonoscopy (PIC): a Randomized Controlled Open-label Trial","Patient-posture and Ileal-intubation During Colonoscopy",2010-06-01,2011-03-01,2011-01-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"School of Digestive and Liver Diseases (SDLD), IPGME & R, Kolkata","Kolkata","India","LMIC"
"59","NCT01053598",2013-02-16,2010-01-19,NA,"Observational",NA,600,"Completed","EVALUATION OF THE PERFORMANCE OF THE NITRATE REDUCTASE AND RESAZURIN TITRE ASSAY FOR THE DETECTION OF MYCOBACTERIUM TUBERCULOSIS COMPLEX FROM SPUTUM IN A HIGH TB AND HIV SETTING","Evaluation Of The Performance Of The Nitrate Reductase And Resazurin Titre Assay For The Detection of Mycobacterium Tuberculosis Complex From Sputum In A High Tb and Hiv Setting",2011-09-01,2012-12-01,2012-09-01,FALSE,NA,NA,"OTHER",FALSE,"Epicentre","Mbarara","Uganda","LMIC"
"60","NCT02768909",2016-05-09,2016-04-11,NA,"Interventional","Not Applicable",250,"Unknown status","Diagnostic Trial to Validate the Use of the E-Nose in Pulmonary TB","Diagnostic Trial to Validate the Use of the E-Nose in Pulmonary TB",2015-01-01,2017-02-01,2016-12-01,FALSE,"Non-Randomized","None (Open Label)","OTHER",FALSE,"Instituto de Biomedicina","Caracas","Venezuela","LMIC"
"61","NCT04150224",2020-02-13,2019-10-18,2020-01-24,"Interventional","Phase 1",60,"Completed","An Open-label, Prospective Study of Safety, Tolerability, Pharmacokinetics and Food Effects of PBTZ169, 80 mg Capsules, When Used in Ascending Doses in Healthy Volunteers","Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169",2018-07-03,2019-02-01,2018-11-23,TRUE,"Randomized","None (Open Label)","INDUSTRY",FALSE,"Clinical hospital at the Yaroslavl station of the Open Joint Stock Company Russian Railways","Yaroslavl","Russian Federation","LMIC"
"62","NCT02536768",2019-07-29,2015-08-26,NA,"Interventional","Not Applicable",8020,"Completed","Evaluation of the National Department of Health's National Adherence Guidelines for Chronic Diseases in South Africa Using Routinely Collected Data","Evaluation of South Africa's National Adherence Strategy",2015-09-01,2018-04-30,2018-04-30,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"Johannesburg Site","Johannesburg","South Africa","LMIC"
"63","NCT00600782",2020-10-02,2008-01-15,NA,"Interventional","Phase 2",45,"Completed","Immunogenicity and Safety of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342) When Administered to Healthy Adults Aged 21 to 40 Years.","Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region",2008-02-05,2008-12-19,2008-12-19,FALSE,"Non-Randomized","None (Open Label)","INDUSTRY",FALSE,"GSK Investigational Site","Worcester","South Africa","LMIC"
"64","NCT02496572",2015-07-09,2014-07-02,NA,"Observational",NA,110,"Unknown status","Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis Treatment in Karakalpakstan, Uzbekistan","Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan",2013-09-01,2016-04-01,2016-03-01,FALSE,NA,NA,"OTHER",FALSE,"Outpatient clinics in three districts","Nukus","Uzbekistan","LMIC"
"65","NCT02533089",2020-03-23,2015-08-20,2020-03-10,"Interventional","Not Applicable",1153,"Completed","Training Lay Healthcare Workers to Optimize TB Care and Improve Outcomes in Malawi","Training Lay Healthcare Workers to Optimize TB Care and Improve Outcomes in Malawi",2016-05-01,2018-02-01,2018-02-01,TRUE,"Randomized",NA,"OTHER",FALSE,"4 Districts, SE zone of Malawi (Balaka, Machinga, Mangochi, Mulanje)","Malawi","Malawi","LMIC"
"66","NCT02457208",2018-10-01,2015-04-22,NA,"Interventional","Phase 1",61,"Completed","Studying the Blood Levels of First-line Anti-tuberculosis Drugs in Relation to Treatment Outcomes Among Newly Diagnosed Adults With Pulmonary Tuberculosis on the Thai-Myanmar Border","PK Study of Anti-TB Drugs",2015-07-07,2018-01-14,2018-01-14,FALSE,NA,"None (Open Label)","OTHER",FALSE,"Shoklo Malaria Research Unit","Mae Sot","Thailand","LMIC"
"67","NCT01371916",2014-08-18,2011-06-08,NA,"Observational",NA,316,"Completed","Diagnosis of Tuberculous Meningitis by a Secretory Antigenic Target 6 (ESAT-6) in CSF","Diagnosis of Tuberculous Meningitis by ESAT-6 in CSF",2010-09-01,2014-01-01,2013-11-01,FALSE,NA,NA,"OTHER",FALSE,"Xijing Hospital","Xi'an","China","LMIC"
"68","NCT00925249",2009-12-11,2009-05-13,NA,"Observational",NA,90,"Unknown status","Comparison of the Tuberculin Skin Test (TST) and QuantiFERON ®-TB Gold Test (QFT-G) In Patients With Rheumatoid Arthritis Being Considered for Anti-TNF-Alpha Therapy","Comparison of the Tuberculin Skin Test (TST) and QuantiFERON ®-TB Gold Test (QFT-G) In Patients With Rheumatoid Arthritis Being Considered for Anti-TNF-Alpha Therapy",2009-05-01,2011-06-01,2011-05-01,FALSE,NA,NA,"FED",FALSE,"Walter Reed Army Medical Center","Washington","United States","HIC"
"69","NCT01830439",2019-09-04,2013-02-12,NA,"Interventional","Phase 1",32,"Completed","A Phase 1, Randomized, Balanced, Single-Dose, Two-Period, Two-Sequence, Crossover, Open-Label Study of the Effect of Food on the Bioavailability and Pharmacokinetics of PA-824 Tablets in Healthy Adult Subjects","Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-009)",2009-09-01,2010-01-01,2010-01-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"MDS Pharma Services (Celerion)","Lincoln","United States","HIC"
"70","NCT00948077",2011-04-11,2009-06-16,NA,"Interventional","Not Applicable",16,"Unknown status","A Single-Center, Open-Label, Randomized, Crossover Design Study to Evaluate the Effect of Dietary Status on Pharmacokinetic Profile of Orally Administered First-Line Anti-TB Drugs in Subjects With Pulmonary Tuberculosis","Pharmacokinetic Study for Anti-tuberculosis Drugs",2009-07-01,2011-12-01,2011-06-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"Taipei Medical University- Wan Fang Hospital","Taipei","Taiwan","HIC"
"71","NCT01038830",2010-06-11,2009-12-23,NA,"Observational",NA,50,"Completed","The Change in Level of Interferon-gamma Assay in Active Tuberculosis Patients During Treatment","QuantiFERON Change During Anti-tuberculosis Medication",2008-05-01,2010-05-01,2010-04-01,FALSE,NA,NA,"OTHER_GOV",FALSE,"Armed Forces Capital Hospital","Seongnam","Korea, Republic of","HIC"
"72","NCT02387242",2017-04-12,2015-02-24,NA,"Interventional","Phase 1",18,"Suspended","Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Single 'High' Doses of Rifampicin in Healthy Volunteers","Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Rifampicin in Healthy Volunteers",2015-02-01,2017-12-01,2017-12-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"National University Hospital","Singapore","Singapore","HIC"
"73","NCT01002170",2010-11-01,2009-07-13,NA,"Observational",NA,30,"Completed","The Impact Factor Analysis of the Therapeutic Drug Monitoring of Oral 2nd Line Antituberculosis Agent, Cycloserine","Pharmacokinetic Study of Patients Who Undergo Cycloserine, a 2nd-line Antituberculosis Medicament",2009-05-01,2010-05-01,2009-06-01,FALSE,NA,NA,"OTHER",FALSE,"Taipei Medical University-Wan Fang Hospital","Taipei","Taiwan","HIC"
"74","NCT03312647",2017-10-12,2017-06-18,NA,"Observational",NA,1000,"Unknown status","Adverse Drug Reactions to Antituberculosis Drugs in the Treatment of Latent Tuberculosis Infection in Korean Health Care Workers","Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection",2017-06-19,2018-05-01,2018-05-01,FALSE,NA,NA,"OTHER",FALSE,"Sang-Heon Kim","Seoul","Korea, Republic of","HIC"
"75","NCT02687529",2019-06-05,2016-02-16,2018-09-18,"Observational",NA,66,"Completed","Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection","Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection",2015-10-27,2016-05-26,2015-11-07,TRUE,NA,NA,"INDUSTRY",FALSE,"VA Palo Alto Health Care System (VAPAHCS)","Palo Alto","United States","HIC"
"76","NCT02331056",2016-10-06,2014-12-15,NA,"Observational",NA,79,"Completed","Could the Stroke Volume Variation Predict a Fluid Responsiveness in Thoracotomy?","Could the Stroke Volume Variation Predict a Fluid Responsiveness in Thoracotomy?",2014-07-01,2015-06-01,2015-06-01,FALSE,NA,NA,"OTHER",FALSE,"Samsung medical center","Seoul","Korea, Republic of","HIC"
"77","NCT01376843",2013-03-04,2011-06-16,NA,"Observational",NA,53,"Completed","Conversion Rate of TST and Quantiferon-TB Gold In Tube Assay in Health Care Workers","Conversion Rate of (TST) Tuberculin Skin Test and Quantiferon-TB Gold In Tube Assay in Health Care Workers",2011-06-01,2012-05-01,2012-05-01,FALSE,NA,NA,"OTHER",FALSE,"Severance Hospital","Seoul","Korea, Republic of","HIC"
"78","NCT01436929",2012-12-13,2011-09-16,NA,"Interventional","Not Applicable",600,"Unknown status","Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs","Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs",2011-09-01,2013-12-01,2013-10-01,FALSE,"Randomized","Quadruple","OTHER",FALSE,"Deog Kyeom Kim","Seoul","Korea, Republic of","HIC"
"79","NCT02690818",2019-04-22,2016-01-05,NA,"Interventional","Not Applicable",30,"Completed","Promoting Adherence to Treatment for Latent TB Infection Through Mobile Phone Text Messaging","Promoting Adherence to Treatment for Latent TB Infection Through Text Messaging",2016-04-01,2018-09-26,2018-09-26,FALSE,"Randomized","Single","OTHER",FALSE,"Pima County Health Department","Tucson","United States","HIC"
"80","NCT01674218",2014-11-13,2012-08-23,NA,"Interventional","Phase 1",74,"Completed","Phase I, Double-Blind, Randomized, Single-Center, Five-Period Crossover Study to Assess the Effects of Single Oral Doses of 400 mg and 1000 mg of PA-824 and 400 mg of PA-824 Plus 400 mg of Moxifloxacin on QTc Interval Compared to Placebo, Using AVELOX™ (Moxifloxacin) as a Positive Control, in Healthy Male and Female Volunteers Aged 18 to 45 Years","Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers",2012-09-01,2012-12-01,2012-12-01,FALSE,"Randomized","Triple","NIH",FALSE,"Quintiles Phase I Services - Overland Park","Overland Park","United States","HIC"
"81","NCT01730664",2017-08-24,2012-11-09,NA,"Interventional","Phase 2",12,"Completed","Pharmacokinetics and Pharmacodynamics of Ertapenem in Patients With Tuberculosis","PK/PD of Ertapenem In Patients With TB",2017-01-26,2017-07-13,2017-07-13,FALSE,NA,"None (Open Label)","OTHER",FALSE,"UMCG - Tuberculosis Center","Groningen","Netherlands","HIC"
"82","NCT01214993",2012-06-07,2010-10-01,NA,"Interventional","Phase 1",38,"Completed","A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects","A Phase 1, Open Label, Placebo-Controlled Study to Evaluate the Effect of GSK1349572 on Iohexol and Para-Aminohippurate Clearance in Healthy Subjects",2010-10-01,2010-11-01,2010-11-01,FALSE,"Randomized","None (Open Label)","INDUSTRY",FALSE,"GSK Investigational Site","Minneapolis","United States","HIC"
"83","NCT01601275",2019-05-14,2012-05-15,NA,"Observational",NA,4600,"Completed","Prospective Database of All Patients With Microbiologically Proven Mycobacteria Tuberculosis Infection Treated at Singapore General Hospital","Database of All Patients With Microbiologically Proven Mycobacteria Tuberculosis Infection",2012-05-01,2018-05-01,2018-05-01,FALSE,NA,NA,"OTHER",FALSE,"Singapore General Hospital","Singapore","Singapore","HIC"
"84","NCT02253537",2019-06-05,2014-09-29,2018-09-18,"Observational",NA,15,"Completed","Evaluation of the 4th Generation QuantiFERON-TB Test (CST001) for the Detection of Tuberculosis Infection","Evaluation of the QuantiFERON-TB Test.",2015-02-02,2016-04-26,2016-04-26,TRUE,NA,NA,"INDUSTRY",FALSE,"University of Washington","Seattle","United States","HIC"
"85","NCT02076139",2018-10-30,2014-02-20,NA,"Interventional","Not Applicable",47,"Completed","Pilot Clinical Trial, Double-blind, Randomized, Placebo Controlled and Masked to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae® Probiotic Administered to Adults With or Without Latent Tuberculosis Infection","Safety and Immunogenicity of Nyaditum Resae® Probiotic to Protect From Tuberculosis",2014-03-01,2015-07-01,2014-06-01,FALSE,"Randomized","Triple","INDUSTRY",FALSE,"Germans Trias I Pujol Hospital","Badalona","Spain","HIC"
"86","NCT02961569",2017-04-26,2016-10-18,NA,"Interventional","Not Applicable",34,"Completed","Comparative Study Between the Classical Strategy and a Faster, Daily Collection for the Diagnosis of Contagious Pulmonary Tuberculosis","Comparison Between Two Strategies for the Diagnosis of TB",2016-07-01,2017-04-01,2017-04-01,FALSE,NA,"None (Open Label)","OTHER",FALSE,"Hôpital Lariboisière","Paris","France","HIC"
"87","NCT02782494",2016-12-13,2016-05-11,NA,"Observational",NA,200,"Unknown status","Comparing Consistency of QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold for Latent Tuberculosis in Dialysis Population","Comparing Consistency of QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold for Latent Tuberculosis in Dialysis Population",2016-05-01,2018-05-01,2018-05-01,FALSE,NA,NA,"OTHER",FALSE,"National Taiwan University Hospital","Taipei","Taiwan","HIC"
"88","NCT01611844",2013-07-30,2011-12-22,NA,"Interventional","Not Applicable",59,"Completed","Optimization of Tuberculosis Intradermal Skin Test: TB Dermatest WP 3.1","Optimization of Tuberculosis Intradermal Skin Test",2011-09-01,2013-04-01,2012-06-01,FALSE,"Randomized","Double","OTHER",FALSE,"Unité de Recherche Clinique en Immunologie Lyon Sud (URCI-LS) et Service d'Immunologie clinique et allergologie-Centre Hospitalier Lyon Sud -Hospices Civils de Lyon","Pierre-Bénite","France","HIC"
"89","NCT01724723",2012-11-07,2012-05-02,NA,"Interventional","Phase 4",50,"Unknown status","Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment","Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment",2012-12-01,2014-06-01,2014-06-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"National Taiwan University Hospital","Taipei","Taiwan","HIC"
"90","NCT01165840",2016-06-09,2010-07-16,2015-10-28,"Interventional","Phase 4",37,"Completed","Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers","Effect of Weight and/or Obesity on Dapsone Drug Concentrations",2010-07-01,2012-05-01,2012-05-01,TRUE,NA,"None (Open Label)","OTHER",FALSE,"University of Texas Southwestern","Dallas","United States","HIC"
"91","NCT00871949",2013-08-26,2009-03-27,NA,"Interventional","Phase 1",19,"Completed","A Phase 1 Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PNU-100480 (PF-02341272) After First Time Administration Of Ascending Oral Doses To Healthy Adult Subjects Under Fed And Fasted Conditions","Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults",2009-04-01,2009-08-01,2009-08-01,FALSE,"Randomized","Double","INDUSTRY",FALSE,"Pfizer Investigational Site","New Haven","United States","HIC"
"92","NCT01358162",2013-05-10,2010-11-18,NA,"Interventional","Phase 1",10,"Completed","A Phase 1C, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 300 mg of SQ109 Given Once Daily for 14 Days in Normal, Healthy Male and Female Volunteers","Phase IC Study of Safety and PK of SQ109 300mg Daily",2010-11-01,2011-04-01,2011-02-01,FALSE,"Randomized","Triple","NIH",FALSE,"Quintiles Phase I Services - Overland Park","Overland Park","United States","HIC"
"93","NCT02782416",2016-12-13,2016-05-11,NA,"Interventional","Not Applicable",800,"Unknown status","A Randomized Study for Screening Latent Tuberculosis Infection and Observing Preventive Therapy in Patients Preparing for Kidney Transplantation","Screening Latent Tuberculosis Infection and Observing Preventive Therapy in Kidney Transplantation",2014-01-01,2017-12-01,2017-12-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"National Taiwan University Hospital","Taipei","Taiwan","HIC"
"94","NCT01242475",2013-01-18,2010-11-16,NA,"Interventional","Phase 2",151,"Completed","A Phase IIa Specificity Trial of the Diagnostic Agent C-Tb, When Given Intradermally by the Mantoux Technique to Healthy Volunteers Previously Vaccinated With BCG","A Trial of the C-Tb Skin Test, When Given Intradermally to Healthy Volunteers Previously Vaccinated With BCG",2011-04-01,2011-11-01,2011-11-01,FALSE,"Randomized","Quadruple","OTHER",FALSE,"Surrey Clinical Research Centre, University of Surrey","Surrey","United Kingdom","HIC"
"95","NCT03665402",2020-02-26,2018-08-21,NA,"Interventional","Not Applicable",16,"Completed","Clinical Trial to Investigate the Appropriate Dose of Isoniazid According to NAT2 Polymorphism Status in Korean Subjects","A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status",2018-05-13,2019-03-31,2018-12-31,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"Seoul National University Hospital Clinical Trials Center","Seoul","Korea, Republic of","HIC"
"96","NCT02216331",2019-09-04,2014-08-12,NA,"Interventional","Phase 1",32,"Completed","A Phase I Open-label Trial to Investigate the Pharmacokinetic Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects","PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)",2010-03-01,2010-05-01,2010-05-01,FALSE,"Randomized","None (Open Label)","OTHER",FALSE,"Celerion (MDS Pharma Services)","Lincoln","United States","HIC"
"97","NCT03423030",2018-07-12,2018-01-24,NA,"Interventional","Phase 1",32,"Completed","Safety, Tolerability, Pharmacokinetic Profile and Ex-vivo Antitubercular Activity of PBTZ169 Formulated as Spray- Dried Dispersion Versus Native Crystal Powder: Single Ascending Doses, Randomized, Placebo- Controlled, Cross-over Phase Ia Trial in Healthy Volunteers","Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation",2017-12-05,2018-03-28,2018-03-28,FALSE,"Randomized","Triple","OTHER",FALSE,"Division of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois (CHUV)","Lausanne","Switzerland","HIC"
"98","NCT02454738",2016-06-06,2015-05-22,NA,"Interventional","Not Applicable",6,"Completed","Ultralow Dose Computed Tomography in Close Contacts at High Risk for Developing Multidrug- or Extensively Drug-resistant Tuberculosis: A Pilot Study","Ultralow Dose Computed Tomography in High-risk Drug-resistant Tuberculosis Contacts",2015-06-01,2016-06-01,2016-06-01,FALSE,NA,"None (Open Label)","OTHER",FALSE,"Seoul National University Hospital","Seoul","Korea, Republic of","HIC"
"99","NCT02013245",2017-02-06,2013-12-03,2016-03-15,"Interventional","Phase 1",36,"Completed","Phase I Double Blind, Randomized, Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC in Comparison With BCG in Elispot TB(ESAT-6, CFP10, PPD)- and HIV- Negative Volunteers","Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine.",2013-01-01,2014-11-01,2014-06-01,TRUE,"Randomized","Quadruple","INDUSTRY",FALSE,"Centre Hospitalier Universitaire Vaudois","Lausanne","Switzerland","HIC"
"100","NCT03149848",2020-08-27,2017-05-09,2018-09-04,"Interventional","Phase 1",15,"Completed","Phase I, Single-center, Open Label, Fixed-sequence Cross-over Study to Evaluate the Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects","Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects",2017-06-06,2017-09-07,2017-09-06,TRUE,"Randomized","None (Open Label)","INDUSTRY",FALSE,"GSK Investigational Site","Cambridge","United Kingdom","HIC"
